Clinical Trial Update: Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating onabotulinumtoxinA (BOTOX) for urinary incontinence due to neurogenic detrusor overactivity in pediatric patients has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Detrusor Overactivity
• Urinary Incontinence

Drugs mentioned

• OnabotulinumtoxinA (Botox) (Botulinum toxin type A)

Snippet

Sponsor: Allergan | Conditions: Urinary Incontinence | Phase 3 | Status: COMPLETED | Results posted: 2019-10-30